Footnotes

Chapter 1 - Introduction

[1]        Journals of the Senate, 23 June 2011, p. 1102.

Chapter 2 - Background

[1]        Department of Health and Ageing, About the PBS, 2011, http://www.pbs.gov.au/info/about-the-pbs (accessed 6 July 2011).

[2]        Visitors from countries which have Reciprocal Health Care Agreement with Australia (RHCA) can also access the scheme.

[3]        Department of Health and Ageing, About the PBS, 2011, http://www.pbs.gov.au/info/about-the-pbs (accessed 6 July 2011).

[4]        Department of Health and Ageing, About the PBS, 2011, http://www.pbs.gov.au/info/about-the-pbs (accessed 6 July 2011).

[5]        Department of Health and Ageing, Pharmaceutical Benefits Advisory Committee, 2011, http://www.pbs.gov.au/info/industry/listing/participants/pbac (accessed 6 July 2011); Department of Health and Ageing, The Listing Steps, http://www.pbs.gov.au/info/industry/listing/listing-steps (accessed 14 July 2011).

[6]        Department of Health and Ageing, Pharmaceutical Benefits Advisory Committee, 2011, http://www.pbs.gov.au/info/industry/listing/participants/pbac (accessed 6 July 2011).

[7]        Department of Health and Ageing, Frequently Asked Questions, 7 January 2010, http://www.health.gov.au/internet/main/publishing.nsf/Content/health-pbs-general-faq.htm-copy2 (accessed  13 July 2011); Department of Health and Ageing, The Listing Steps – Step 1: Seek advice from the PEB (Optional but recommended), http://www.pbs.gov.au/info/industry/listing/listing-steps/a-seek-advice-from-peb (accessed 14 July 2011).

[8]        Department of Health and Ageing, The Listing Steps, http://www.pbs.gov.au/info/industry/listing/listing-steps (accessed 14 July 2011).

[9]        Department of Health and Ageing, About the PBS, 2011, http://www.pbs.gov.au/info/about-the-pbs (accessed 6 July 2011); Department of Health and Ageing, The Listing Steps – Step 4: Send response, http://www.pbs.gov.au/info/industry/listing/listing-steps/d-send-response (accessed 14 July 2011).

[10]      Department of Health and Ageing, The Listing Steps, http://www.pbs.gov.au/info/industry/listing/listing-steps (accessed 14 July 2011).

[11]      Department of Health and Ageing, The Listing Steps, http://www.pbs.gov.au/info/industry/listing/listing-steps (accessed 14 July 2011).

[12]      Department of Health and Ageing, The Listing Steps, http://www.pbs.gov.au/info/industry/listing/listing-steps (accessed 14 July 2011); Department of Health and Ageing, The Listing Steps – Step 9: Agreement on usage estimates, http://www.pbs.gov.au/info/industry/listing/listing-steps/i-agreement-on-estimates (accessed 14 July 2011); Commonwealth Government, Portfolio Budget Statements 2011–12: Budget Related Paper No. 1.10: Health and Ageing Portfolio, Commonwealth of Australia, Canberra, 2011, p. 121; Parliamentary Library, 'Making savings from the PBS – is deferring the listing of medicines the answer?', Flagpost, 4 April 2011, http://parliamentflagpost.blogspot.com/2011/04/making-savings-from-pbs-is-deferring.html (accessed 6 July 2011).

[13]      Department of Health and Ageing, The Listing Steps – Step 10: Formal advice of listing, http://www.pbs.gov.au/info/industry/listing/listing-steps/j-formal-advice-of-listing (accessed 14 July 2011).

[14]      Department of Health and Ageing, PBAC Outcomes, http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/pbac-outcomes (accessed 14 July 2011).

[15]      Department of Health and Ageing, About the PBS, 2011, http://www.pbs.gov.au/info/about-the-pbs (accessed 6 July 2011).

[16]      Parliamentary Library, 'Making savings from the PBS – is deferring the listing of medicines the answer?', Flagpost, 4 April 2011, http://parliamentflagpost.blogspot.com/2011/04/making-savings-from-pbs-is-deferring.html (accessed 6 July 2011).

[17]      Department of Health and Ageing, The Impact of PBS Reform: Report to Parliament on the National Health Amendment (Pharmaceutical Benefits Scheme) Act 2007, 2010, p. 28.

[18]      Department of Health and Ageing, The Impact of PBS Reform: Report to Parliament on the National Health Amendment (Pharmaceutical Benefits Scheme) Act 2007, 2010, pp 31–35.

[19]      Department of Health and Ageing, The Impact of PBS Reform: Report to Parliament on the National Health Amendment (Pharmaceutical Benefits Scheme) Act 2007, 2010, pp 31–35.

[20]      Department of Health and Ageing, The Impact of PBS Reform: Report to Parliament on the National Health Amendment (Pharmaceutical Benefits Scheme) Act 2007, 2010, pp 35–36.

[21]      Parliamentary Library, 'Making savings from the PBS – is deferring the listing of medicines the answer?', Flagpost, 4 April 2011, http://parliamentflagpost.blogspot.com/2011/04/making-savings-from-pbs-is-deferring.html (accessed 6 July 2011).

[22]      Commonwealth Government and Medicines Australia, Memorandum of Understanding, 6 May 2010, p. 1.

[23]      Parliamentary Library, Bills Digest No. 13, 2010–11, National Health Amendment (Pharmaceutical Benefits Scheme) Bill 2010, 15 October 2010, p. 3.

[24]      Medicines Australia, PBS MOU, May 2010, http://medicinesaustralia.com.au/issues-information/pbs-mou/ (accessed 13 July 2011).

[25]      Department of Health and Ageing, Memorandum of Understanding with Medicines Australia, September 2010, http://www.pbs.gov.au/info/industry/useful-resources/memorandum (accessed 13 July 2011).

[26]      The Hon. Nicola Roxon, MP, Minister for Health and Ageing, 'Patients benefit from new medicines listed on the PBS and NIP', Media Release, 25 February 2011, [p.2]; Research Australia, Submission 12, [pp 1–2].

[27]      The Hon. Nicola Roxon, MP, Minister for Health and Ageing, Transcript of Doorstop, Melbourne, 25 February 2011, [pp 1 and 5–6].

[28]      The Hon. Nicola Roxon, MP, Minister for Health and Ageing, Transcript of Doorstop, Melbourne, 25 February 2011, [p. 5].

[29]      The Hon. Nicola Roxon, MP, Minister for Health and Ageing, 'Opening Address to Consumers Health Forum PBS Summit', Speech, 29 April 2011, [p. 4].

[30]      Commonwealth Government, Portfolio Budget Statements 2011–12: Budget Related Paper No. 1.10: Health and Ageing Portfolio, Commonwealth of Australia, Canberra, 2011, p. 121.

[31]      The Hon. Nicola Roxon, MP, Minister for Health and Ageing, Transcript of Doorstop, Adelaide, 7 March 2011, [pp 4–5].

[32]      The Hon. Nicola Roxon, MP, Minister for Health and Ageing, 'Opening Address to Consumers Health Forum PBS Summit', Speech, 29 April 2011, [pp 2–3].

[33]      The Hon. Nicola Roxon, MP, Minister for Health and Ageing, Transcript of Doorstop, Melbourne, 25 February 2011,[ p. 4].

[34]      Consumers Health Forum of Australia, Summary of Outcomes: PBS Deferral Decision Forum, 29 April 2011, [pp 1–3].

[35]      Parliamentary Library, 'Making savings from the PBS – is deferring the listing of medicines the answer?', Flagpost, 4 April 2011, http://parliamentflagpost.blogspot.com/2011/04/making-savings-from-pbs-is-deferring.html (accessed 6 July 2011).

[36]      Deakin Health Economics, Deakin University, Submission 19, p. 2; Mr David Learmonth, Deputy Secretary, Department of Health and Ageing, Committee Hansard, 25 July 2011, p. 10.

[37]      Consumers Health Forum of Australia, Summary of Outcomes: PBS Deferral Decision Forum, 29 April 2011, [p. 3].

Chapter 3 - The Government's decision to defer the listing of medicines under the Pharmaceutical Benefits Scheme

[1]        Arthritis Australia, Submission 25, pp 1–2.

[2]        Ms Carol Bennett, Chief Executive Officer, Consumers Health Forum of Australia, Committee Hansard, 25 July 2011, p. 35. See also Ms Helen Tyrrell, Chief Executive Officer, Hepatitis Australia, Committee Hansard, 25 July 2011, pp 52–53.

[3]        The Hon. Nicola Roxon, MP, Minister for Health and Ageing, Press Conference – Canberra, Transcript, 21 June 2011, [p. 3].

[4]        Australian Pain Management Association, Submission 14, p. 5; Mr Paul Murdoch, Vice-President, Australian Pain Management Association, Committee Hansard, 21 July 2011, p. 46.

[5]        Chronic Illness Alliance, Submission 4, pp 2–3; National Association of People Living With HIV/AIDS, Submission 6, pp 2–3.

[6]        Chronic Illness Alliance, Submission 4, p. 5; National Association of People Living With HIV/AIDS, Submission 6, pp 3–4; Council of Social Service Network, Submission 7, p. 5; Consumers Health Forum of Australia, Submission 9, p. 4. See also Dr Christine Walker, Executive Officer, Chronic Illness Alliance, Committee Hansard, 21 July 2011, p. 39; Dr Brendan Shaw, Chief Executive, Medicines Australia, Committee Hansard, 25 July 2011, p. 25; Diabetes Australia, Submission 5, [p. 1]; The Australian Lung Foundation, Submission 20, [p. 1].

[7]        Mr David Learmonth, Deputy Secretary, Department of Health and Ageing, Committee Hansard, 25 July 2011, p. 2.

[8]        Ms Carol Bennett, Chief Executive Officer, Consumers Health Forum of Australia, Committee Hansard, 25 July 2011, p. 35. See also Ms Helen Tyrrell, Chief Executive Officer, Hepatitis Australia, Committee Hansard, 25 July 2011, pp 52–53.

[9]        Ms Carol Bennett, Chief Executive Officer, Consumers Health Forum of Australia, Committee Hansard, 25 July 2011, p. 40.

[10]      The Hon. Nicola Roxon, MP, Minister for Health and Ageing, 'Opening Address to Consumers Health Forum PBS Summit', Speech, 29 April 2011, [p. 3].

[11]      Ms Helen Tyrrell, Chief Executive Officer, Hepatitis Australia, Committee Hansard, 25 July 2011, p. 52.

[12]      Ms Helen Tyrrell, Chief Executive Officer, Hepatitis Australia, Committee Hansard, 25 July 2011, p. 52.

[13]      Mr David Learmonth, Deputy Secretary, Department of Health and Ageing, Committee Hansard, 25 July 2011, p. 5.

[14]      Australian Medical Association, Submission 16, p. 3.

[15]      Hepatitis Australia, Submission 21, p. 3.

[16]      Ms Helen Tyrrell, Chief Executive Officer, Hepatitis Australia, Committee Hansard, 25 July 2011, p. 52.

[17]      The Hon. Nicola Roxon, MP, Minister for Health and Ageing, 'Opening Address to Consumers Health Forum PBS Summit', Speech, 29 April 2011, [p.4].

[18]      Dr Brendan Shaw, Chief Executive, Medicines Australia, Committee Hansard, 25 July 2011, p. 26.

[19]      Mr David Menadue, Special Representative, National Association of People Living with HIV/AIDS, Committee Hansard, 21 July 2011, p. 48.

[20]      National Association of People Living With HIV/AIDS, Submission 6, p. 3. See also Dr Brendan Shaw, Chief Executive, Medicines Australia, Committee Hansard, 25 July 2011, p. 25; Ms Carol Bennett, Chief Executive Officer, Consumers Health Forum of Australia, Committee Hansard, 25 July 2011, p. 35; Australian Pain Management Association, Submission 14, p. 3; Osteoporosis Australia, Submission 22, [p. 1].

[21]      Mr John Latham, Chairman and Managing Director, Pfizer Australia, Committee Hansard, 21 July 2011, p. 27.

[22]      Mr David Menadue, Special Representative, National Association of People Living with HIV/AIDS, Committee Hansard, 21 July 2011, p. 48; Ms Carol Bennett, Chief Executive Officer, Consumers Health Forum of Australia, Committee Hansard, 25 July 2011, p. 35; Mr John William Stubbs, Executive Officer, Cancer Voices Australia, Committee Hansard, 25 July 2011, p. 44; Ms Barbara Hocking, Executive Director, SANE Australia, Committee Hansard, 25 July 2011, p. 49.

[23]      Australian Medical Association, Submission 16, p. 2.

[24]      Mr David Menadue, Special Representative, National Association of People Living with HIV/AIDS, Committee Hansard, 21 July 2011, p. 48.

[25]      Mr David Menadue, Special Representative, National Association of People Living with HIV/AIDS, Committee Hansard, 21 July 2011, p. 48.

[26]      Ms Carol Bennett, Chief Executive Officer, Consumers Health Forum of Australia, Committee Hansard, 25 July 2011, p. 35.

[27]      Ms Carol Bennett, Chief Executive Officer, Consumers Health Forum of Australia, Committee Hansard, 25 July 2011, p. 35.

[28]      iNova Pharmaceuticals (Australia), Submission 11, p. 3. See also Dr Brendan Shaw, Chief Executive, Medicines Australia, Committee Hansard, 25 July 2011, p. 25; Ms Helen Tyrrell, Chief Executive Officer, Hepatitis Australia, Committee Hansard, 25 July 2011, p. 53; Council of Social Service Network, Submission 7, p. 5.

[29]      National Association of People Living With HIV/AIDS, Submission 6, p. 3; Council of Social Service Network, Submission 7, p. 5; Consumers Health Forum of Australia, Submission 9, p. 4.

[30]      Council of Social Service Network, Submission 7, p. 5.

[31]      Consumers Health Forum of Australia, Submission 9, p. 4. See also Dr Christine Walker, Executive Officer, Chronic Illness Alliance, Committee Hansard, 21 July 2011, p. 39; Ms Geraldine Robertson, Submission 2, [p. 1]; Cancer Voices Australia, Submission 8, p. 2; Cystic Fibrosis Australia, Submission 18, [p. 1].

[32]      Ms Carol Bennett, Chief Executive Officer, Consumers Health Forum of Australia, Committee Hansard, 25 July 2011, p. 36.

[33]      Cystic Fibrosis Australia, Submission 18, p. 1. See also Ms Carol Bennett, Chief Executive Officer, Consumers Health Forum of Australia, Committee Hansard, 25 July 2011, p. 35.

[34]      National Association of People Living With HIV/AIDS, Submission 6, p. 3.

[35]      Ms Helen Tyrrell, Chief Executive Officer, Hepatitis Australia, Committee Hansard, 25 July 2011, p. 52.

[36]      Department of Health and Ageing, Submission 46, p. 10.

[37]      Ms Liliana Bulfone, Senior Research Fellow, Deakin University, Committee Hansard, 21 July 2011, p. 1.

[38]      Ms Liliana Bulfone, Senior Research Fellow, Deakin University, Committee Hansard, 21 July 2011, p. 1. See also Ms Carol Bennett, Chief Executive Officer, Consumers Health Forum of Australia, Committee Hansard, 25 July 2011, p. 36; Ms Helen Tyrrell, Chief Executive Officer, Hepatitis Australia, Committee Hansard, 25 July 2011, p. 52; Hepatitis Australia, Submission 21, p. 3.

[39]      Dr Bill Ketelbey, Country Medical Director, Pfizer Australia, Committee Hansard, 21 July 2011, p. 27.

[40]      Dr Bill Ketelbey, Country Medical Director, Pfizer Australia, Committee Hansard, 21 July 2011, p. 27.

[41]      AstraZeneca Australia, Submission 47, p. 12.

[42]      Mr David Learmonth, Deputy Secretary, Department of Health and Ageing, Committee Hansard, 25 July 2011, pp 3–4.

[43]      Janssen-Cilag Australia, answers to questions on notice and additional information, 21 July 2011, pp 1–2.

[44]      Positive Life NSW, Submission 26, pp 3–4. See also ACON, Submission 26, [p. 1].

[45]      Mr David Learmonth, Deputy Secretary, Department of Health and Ageing, Committee Hansard, 25 July 2011, p. 2.

[46]      Ms Carol Bennett, Chief Executive Officer, Consumers Health Forum of Australia, Committee Hansard, 25 July 2011, p. 36. See also Ms Helen Tyrrell, Chief Executive Officer, Hepatitis Australia, Committee Hansard, 25 July 2011, p. 52; Hepatitis Australia, Submission 21, p. 3.

[47]      AstraZeneca Australia, Submission 47, p. 9.

[48]      Mr David Learmonth, Deputy Secretary, Department of Health and Ageing, Committee Hansard, 25 July 2011, p. 5.

[49]      Department of Health and Ageing, Submission 46, p. 10.

[50]      Mr David Learmonth, Deputy Secretary, Department of Health and Ageing, Committee Hansard, 25 July 2011, p. 5.

[51]      Deakin Health Economics, Deakin University, Submission 19, p. 3; Breast Cancer Network Australia, Submission 24, p. 3.

[52]      Cancer Council Australia, the Clinical Oncological Society of Australia and the Medical Oncology Group of Australia, Submission 32, p. 2.

[53]      Consumers Health Forum of Australia, Submission 9, p. 4.

[54]      Deakin Health Economics, Deakin University, Submission 19, p. 3.

[55]      Mr Paul Murdoch, Vice-President, Australian Pain Management Association, Committee Hansard, 21 July 2011, p. 45.

[56]      Mr David Learmonth, Deputy Secretary, Department of Health and Ageing, Committee Hansard, 25 July 2011, p. 6.

[57]      Mr David Menadue, Special Representative, National Association of People Living with HIV/AIDS, Committee Hansard, 21 July 2011, p. 48.

[58]      Mr Mark Glover, Vice President and Managing Director, Allergan Australia, Committee Hansard, 21 July 2011, p. 23.

[59]      Mr John Latham, Chairman and Managing Director, Pfizer Australia, Committee Hansard, 21 July 2011, p. 27.

[60]      National Association of People Living With HIV/AIDS, Submission 6, p. 2.

[61]      Dr Brendan Shaw, Chief Executive, Medicines Australia, Committee Hansard, 25 July 2011, p. 33. See also Dr Simon Fisher, Medical Director, AstraZeneca Australia, Committee Hansard, 21 July 2011, pp 18–19.

[62]      Dr Simon Fisher, Medical Director, AstraZeneca Australia, Committee Hansard, 21 July 2011, pp 18–19.

[63]      Dr Brendan Shaw, Chief Executive, Medicines Australia, Committee Hansard, 25 July 2011, p. 33.

[64]      Dr Brendan Shaw, Chief Executive, Medicines Australia, Committee Hansard, 25 July 2011, p. 33. See also Dr Simon Fisher, Medical Director, AstraZeneca Australia, Committee Hansard, 21 July 2011, pp 18–19.

[65]      Dr Brendan Shaw, Chief Executive, Medicines Australia, Committee Hansard, 25 July 2011, pp 30–31.

[66]      Chronic Illness Alliance, Submission 4, p. 5; National Association of People Living With HIV/AIDS, Submission 6, pp 3–4; Council of Social Service Network, Submission 7, p. 5; Consumers Health Forum of Australia, Submission 9, p. 4. See also Dr Christine Walker, Executive Officer, Chronic Illness Alliance, Committee Hansard, 21 July 2011, p. 39; Dr Brendan Shaw, Chief Executive, Medicines Australia, Committee Hansard, 25 July 2011, p. 25; Diabetes Australia, Submission 5, [p. 1]; The Australian Lung Foundation, Submission 20, [p. 1]; Australian Medical Association, Submission 16, p. 2.

[67]      Medicines Australia, Submission 36, p. 8.

[68]      Ms Carol Bennett, Chief Executive Officer, Consumers Health Forum of Australia, Committee Hansard, 25 July 2011, pp 35–36.

[69]      Medicines Australia, Submission 36, p. 7.

[70]      Medicines Australia, Submission 36, p. 8.

[71]      Medicines Australia, Submission 36, p. 8.

[72]      Ms Sandra Younie, Senior Research Fellow, Deakin University, Committee Hansard, 21 July 2011, p. 2.

[73]      Dr Christine Walker, Executive Officer, Chronic Illness Alliance, Committee Hansard, 21 July 2011, p. 39. See also Mr David Menadue, Special Representative, National Association of People Living with HIV/AIDS, Committee Hansard, 21 July 2011, pp 48–49.

[74]      Mental Health Council of Australia, Submission 53, p. 4.

[75]      Ms Carol Bennett, Chief Executive Officer, Consumers Health Forum of Australia, Committee Hansard, 25 July 2011, p. 37. See also Arthritis Australia, Submission 25, p. 2.

[76]      Mr Matthew Pitt, Chair, Brain Tumour Alliance Australia, Committee Hansard, 25 July 2011, p. 46.

[77]      AstraZeneca Australia, Submission 47, p. 1.

[78]      Australian Pain Management Association, Submission 14, p. 5.

[79]      Mr Paul Murdoch, Vice-President, Australian Pain Management Association, Committee Hansard, 21 July 2011, p. 46.

[80]      Australian Pain Management Association, Submission 14, p. 5.

[81]      Mr Paul Murdoch, Vice-President, Australian Pain Management Association, Committee Hansard, 21 July 2011, p. 46. See also Professor Michael Cousins, Director, Pain Australia, Committee Hansard, 21 July 2011, p. 46.

[82]      Mr John Latham, Chairman and Managing Director, Pfizer Australia, Committee Hansard, 21 July 2011, p. 30.

[83]      Mr John Latham, Chairman and Managing Director, Pfizer Australia, Committee Hansard, 21 July 2011, p. 30.

[84]      Mr Paul Murdoch, Vice-President, Australian Pain Management Association, Committee Hansard, 21 July 2011, p. 44. See also Mr David Menadue, Special Representative, National Association of People Living with HIV/AIDS, Committee Hansard, 21 July 2011, p. 48.

[85]      Mr John Latham, Chairman and Managing Director, Pfizer Australia, Committee Hansard, 21 July 2011, p. 30.

[86]      Mr David Learmonth, Deputy Secretary, Department of Health and Ageing, Committee Hansard, 25 July 2011, p. 3.

[87]      Research Australia, Submission 12, [p. 2]; Mr Mark Glover, Vice President and Managing Director, Allergan Australia, Committee Hansard, 21 July 2011, p. 16; Dr Brendan Shaw, Chief Executive, Medicines Australia, Committee Hansard, 25 July 2011, p. 29; Novo Nordisk, Submission 23, [pp 2–3];

[88]      Mr John Latham, Chairman and Managing Director, Pfizer Australia, Committee Hansard, 21 July 2011, p. 27.

[89]      Mr John Latham, Chairman and Managing Director, Pfizer Australia, Committee Hansard, 21 July 2011, p. 27.

[90]      Deakin Health Economics, Deakin University, Submission 19, p. 6.

[91]      National Association of People Living With HIV/AIDS, Submission 6, p. 2; Dr Brendan Shaw, Chief Executive, Medicines Australia, Committee Hansard, 25 July 2011, pp 25 and 28; Ms Carol Bennett, Chief Executive Officer, Consumers Health Forum of Australia, Committee Hansard, 25 July 2011, p. 40; Cancer Voices Australia, Submission 8, p. 4; Painaustralia, Submission 15, p. 2.

[92]      Dr Brendan Shaw, Chief Executive, Medicines Australia, Committee Hansard, 25 July 2011, p. 29.

[93]      Ms Helen Tyrrell, Chief Executive Officer, Hepatitis Australia, Committee Hansard, 25 July 2011, p. 53.

[94]      Mundipharma, answers to questions on notice and additional information, 21 July 2011, p. 4.

[95]      Mundipharma, answers to questions on notice and additional information, 21 July 2011, p. 4.

Chapter 4 - Financial impact of the Pharmaceutical Benefits Scheme on the Commonwealth Budget

[1]        Commonwealth Government, Portfolio Budget Statements 2011–12: Budget Related Paper No. 1.10: Health and Ageing Portfolio, Commonwealth of Australia, Canberra, 2011, p. 121.

[2]        Mr David Learmonth, Deputy Secretary, Department of Health and Ageing, Committee Hansard, 25 July 2011, p. 11; Mr David De Carvalho, First Assistant Secretary, Social Policy Division, Budget Group, Department of Finance and Deregulation, Committee Hansard, 25 July 2011, p. 11.

[3]        Department of Health and Ageing, Submission 46, p. 7.

[4]        Mr David Learmonth, Deputy Secretary, Department of Health and Ageing, Committee Hansard, 25 July 2011, p. 1.

[5]        Mr Mark Glover, Vice President and Managing Director, Allergan Australia, Committee Hansard, 21 July 2011, p. 24.

[6]        Medicines Australia, Submission 36, p. 24.

[7]        Medicines Australia, Submission 36, p. 25.

[8]        Medicines Australia, Submission 36, p. 27.

[9]        Generic Medicines Industry Association, Submission 31, p. 4.

[10]      Generic Medicines Industry Association, Submission 31, p. 4.

[11]      Mr Robert Ellis, Board Member, Generic Medicines Industry Association, Committee Hansard, 21 July 2011, p. 12.

[12]      SANE Australia, Submission 10, [p. 2]. See also iNova Pharmaceuticals (Australia), Submission 11, p. 2; Council of Social Service Network, Submission 7, p. 5.

[13]      Dr Brendan Shaw, Chief Executive, Medicines Australia, Committee Hansard, 25 July 2011, p. 25.

[14]      Deakin Health Economics, Deakin University, Submission 19, pp 2–3.

[15]      The Hon. Nicola Roxon, MP, Minister for Health and Ageing, Press Conference – Canberra, Transcript, 21 June 2011, [p. 3].

[16]      Department of Health and Ageing, Submission 46, p. 16.

[17]      Dr Brendan Shaw, Chief Executive, Medicines Australia, Committee Hansard, 25 July 2011, p. 26.

[18]      Australian Medical Association, Submission 16, p. 2; Ms Liliana Bulfone, Senior Research Fellow, Deakin University, Committee Hansard, 21 July 2011, p. 2. See also Ms Carol Bennett, Chief Executive Officer, Consumers Health Forum of Australia, Committee Hansard, 25 July 2011, p. 41.

[19]      Ms Liliana Bulfone, Senior Research Fellow, Deakin University, Committee Hansard, 21 July 2011, p. 2.

[20]      Council of Social Service Network, Submission 7, p. 5.

[21]      Council of Social Service Network, Submission 7, p. 5.

[22]      Government of Western Australia, Department of Health, Submission 63, p. 2.

[23]      Research Australia, Submission 12, [p. 3]; Chronic Illness Alliance, Submission 4, pp 4–5; Dr Christine Walker, Executive Officer, Chronic Illness Alliance, Committee Hansard, 21 July 2011, p. 39; Mental Illness Fellowship of Australia, Submission 13, pp 2–3; Diabetes Australia, Submission 6, p. 2; Private Mental Health Consumer Carer Network (Australia), Submission 1, p. 2; Mr Bruce Goodwin, Managing Director, Janssen-Cilag Australia, Committee Hansard, 21 July 2011, p. 28; Ms Helen Tyrrell, Chief Executive Officer, Hepatitis Australia, Committee Hansard, 25 July 2011, p. 53; Council of Social Service Network, Submission 7, p. 5; Brain Tumour Alliance Australia, Submission 17, p. 5; Breast Cancer Network Australia, Submission 24, p. 3; Arthritis Australia, Submission 25, p. 2; National Seniors Australia, Submission 50, p. 2; The Royal Australasian College of Physicians, Submission 61, p. 1.

[24]      Australian Medical Association, Submission 16, p. 2.

[25]      Diabetes Australia, Submission 5, p. 1; Council of Social Service Network, Submission 7, p. 5; Ms Barbara Hocking, Executive Director, SANE Australia, Committee Hansard, 25 July 2011, p. 49.

[26]      Ms Carol Bennett, Chief Executive Officer, Consumers Health Forum of Australia, Committee Hansard, 25 July 2011, p. 36. See also Mr Brian Stafford, Submission 3, [pp 1–2].

[27]      Cancer Council Australia, the Clinical Oncological Society of Australia and the Medical Oncology Group of Australia, Submission 32, p. 2.

[28]      National Association of People Living with HIV/AIDS, Submission 6, p. 1.

[29]      Dr John Whitlam, Medical Affairs Director, Mundipharma, Committee Hansard, 21 July 2011, p. 32.

[30]      Dr John Whitlam, Medical Affairs Director, Mundipharma, Committee Hansard, 21 July 2011, p. 32.

[31]      Multiple Sclerosis (MS) Australia, Submission 43, pp 5–6.

[32]      Northern Territory Government, Department of Health, Submission 62, p. 2.

[33]      Mr Andrew Bruce, Executive Director, Health Policy and Research, Medicines Australia, Committee Hansard, 25 July 2011, p. 34.

[34]      Dr Brendan Shaw, Chief Executive, Medicines Australia, Committee Hansard, 25 July 2011, p. 25.

[35]      Dr Brendan Shaw, Chief Executive, Medicines Australia, Committee Hansard, 25 July 2011, p. 26.

[36]      Australian Medical Association, Submission 16, pp 3–4.

[37]      Generic Medicines Industry Association, Submission 31, p. 4.

[38]      Generic Medicines Industry Association, Submission 31, p. 4.

[39]      Generic Medicines Industry Association, Submission 31, p. 4.

[40]      Generic Medicines Industry Association, Submission 31, pp 6–7.

[41]      Generic Medicines Industry Association, Submission 31, pp 5–6.

[42]      Mr John Latham, Chairman and Managing Director, Pfizer Australia, Committee Hansard, 21 July 2011, p. 31.

[43]      Chronic Illness Alliance, Submission 4, pp 5–6.

[44]      Ms Liliana Bulfone, Senior Research Fellow, Deakin University, Committee Hansard, 21 July 2011, pp 2–3.

[45]      Mr Mark Glover, Vice President and Managing Director, Allergan Australia, Committee Hansard, 21 July 2011, p. 23.

[46]      GlaxoSmithKline Australia, Submission 44, p. 3.

[47]      Generic Medicines Industry Association, Submission 31, p. 4.

Chapter 5 - Consequences for patients

[1]        iNova Pharmaceuticals (Australia), Submission 11, p. 2.

[2]        Consumers Health Forum of Australia, Submission 9, Attachment A 'Keep your Cabinet out of our medicines: Results of a consumer survey on changes to the PBS listing process', April 2011, p. 4. See also Ms Carol Bennett, Chief Executive Officer, Consumers Health Forum of Australia, Committee Hansard, 25 July 2011, pp 39–40.

[3]        Ms Liliana Bulfone, Senior Research Fellow, Deakin University, Committee Hansard, 21 July 2011, p. 4.

[4]        Council of Social Service Network, Submission 7, p. 4; Cancer Voices Australia, Submission 8, p. 2; Private Mental Health Consumer Carer Network (Australia), Submission 1, p. 2; Research Australia, Submission 12, [p. 3]; Roche Products, Submission 39, p. 4; Brain Tumour Alliance Australia, Submission 17, p. 2.

[5]        Council of Social Service Network, Submission 7, pp 4–5.

[6]        National Seniors Australia, Submission 50, p. 1.

[7]        Cancer Voices Australia, Submission 8, p. 2; Brain Tumour Alliance Australia, Submission 17, p. 2.

[8]        Chronic Illness Alliance, Submission 4, pp 3–4; Council of Social Service Network, Submission 7, pp 4–5; Australian Pain Management Association, Submission 14, p. 5.

[9]        Chronic Illness Alliance, Submission 4, p. 4.

[10]      Private Mental Health Consumer Carer Network (Australia), Submission 1, p. 2.

[11]      MS Australia, Submission 43, p. 6.

[12]      GlaxoSmithKline Australia, Submission 44, p. 9. See also Chronic Illness Alliance, Submission 4, p. 3; AstraZeneca Australia, Submission 47, p. 1; Medicines Australia, Submission 36, p. 13.

[13]      Mr Robert Pask, National Advocates Program, Multiple Sclerosis Australia, Committee Hansard, 21 July 2011, p. 42. For another example, see Mr John Stubbs, Executive Officer, Cancer Voices Australia, Committee Hansard, 25 July 2011, p. 46.

[14]      Ms Carol Bennett, Chief Executive Officer, Consumers Health Forum of Australia, Committee Hansard, 25 July 2011, pp 39–40.

[15]      GlaxoSmithKline Australia, Submission 44, p. 9.

[16]      Ms Elizabeth Graham, Submission 54, [pp 1–2].

[17]      Council of Social Service Network, Submission 7, pp 4–5. See also Health Consumer's Council (WA), Submission 33, [p. 2].

[18]      Consumers Health Forum of Australia, Submission 9, Attachment A 'Keep your Cabinet out of our medicines: Results of a consumer survey on changes to the PBS listing process', April 2011, p. 4.

[19]      National Association of People Living with HIV/AIDS, Submission 6, p. 4; iNova Pharmaceuticals (Australia), Submission 11, p. 2; Dr Brendan Shaw, Chief Executive, Medicines Australia, Committee Hansard, 25 July 2011, p. 25.

[20]      Dr Brendan Shaw, Chief Executive, Medicines Australia, Committee Hansard, 25 July 2011, p. 32.

[21]      Mr Brian Stafford, Submission 3, p. 1.

[22]      Pfizer Australia, Submission 35, p. 14.

[23]      Diabetes Australia, Submission 5, [p. 1].

[24]      Mr Jose Vieira, Managing Director, and Dr Simon Fisher, Medical Director, AstraZeneca Australia, Committee Hansard, 21 July 2011, pp 19 and 22.

[25]      AstraZeneca Australia, Submission 47, p. 5.

[26]      Northern Territory Government, Department of Health, Submission 62, p. 1.

[27]      Cancer Voices Australia, Submission 8, p. 2; Private Mental Health Consumer Carer Network (Australia), Submission 1, p. 2.

[28]      Dr Simon Fisher, Medical Director, AstraZeneca Australia, Committee Hansard, 21 July 2011, p. 18.

[29]      Mr Paul Murdoch, Vice-President, Australian Pain Management Association, Committee Hansard, 21 July 2011, p. 45. See also Australian Medical Association, Submission 16, p. 2; Medicines Australia, Submission 36, p. 14.

[30]      Ms Anna Wise, Senior Policy Manager, Consumers Health Forum of Australia, Committee Hansard, 25 July 2011, p. 41.

[31]      GlaxoSmithKline Australia, Submission 44, p. 9. See also Breast Cancer Network of Australia, Submission 24, p. 2; Pfizer Australia, Submission 35, p. 14; Ms Elizabeth Graham, Submission 54, [p. 2]; Fabry Support Group Australia, Submission 60, [p. 2].

[32]      Consumers Health Forum of Australia, Submission 9, Attachment A 'Keep your Cabinet out of our medicines: Results of a consumer survey on changes to the PBS listing process', April 2011, p. 5.

[33]      Ms Carol Bennett, Chief Executive Officer, Consumers Health Forum of Australia, Committee Hansard, 25 July 2011, p. 38. See also Mr Matthew Pitt, Chair, Brain Tumour Alliance Australia, Committee Hansard, 25 July 2011, p. 46.

[34]      Ms Liliana Bulfone, Senior Research Fellow, Deakin University, Committee Hansard, 21 July 2011, pp 1–2. See also Deakin Health Economics, Deakin University, Submission 19, p. 5; Joint submission from Cancer Council Australia, the Clinical Oncological Society of Australia and the Medical Oncology Group of Australia, Submission 32, p. 2.

[35]      Dr Brendan Shaw, Chief Executive, Medicines Australia, Committee Hansard, 25 July 2011, p. 31.

[36]      Dr Simon Fisher, Medical Director, AstraZeneca Australia, Committee Hansard, 21 July 2011, p. 19.

[37]      Mr Mark Glover, Vice President and Managing Director, Allergan Australia, and Dr Bill Ketelbey, Country Medical Director, Pfizer Australia, Committee Hansard, 21 July 2011, pp 19 and 27–28; Dr Brendan Shaw, Chief Executive, Medicines Australia, Committee Hansard, 25 July 2011, p. 25. See also Ms Helen Tyrrell, Chief Executive Officer, Hepatitis Australia, Committee Hansard, 25 July 2011, p. 52; Sanofi, Submission 29, [p. 2].

[38]      Cancer Voices Australia, Submission 8, p. 2.

[39]      Consumers Health Forum of Australia, Submission 9, p. 3. See also Ms Helen Tyrrell, Chief Executive Officer, Hepatitis Australia, Committee Hansard, 25 July 2011, p. 52.

[40]      Consumers Health Forum of Australia, Submission 9, p. 3.

[41]      Mr Matthew Pitt, Chair, Brain Tumour Alliance Australia, Committee Hansard, 25 July 2011, p. 48.

[42]      Ms Helen Tyrrell, Chief Executive Officer, Hepatitis Australia, Committee Hansard, 25 July 2011, pp 52, 55 and 56.

[43]      GlaxoSmithKline Australia, Submission 44, p. 10.

[44]      Mr Denis Strangman, Secretary, Brain Tumour Alliance Australia, Committee Hansard, 25 July 2011, p. 45.

[45]      Consumers Health Forum of Australia, Submission 9, p. 3; Ms Carol Bennett, Chief Executive Officer, Consumers Health Forum of Australia, Committee Hansard, 25 July 2011, p. 36.

[46]      Ms Carol Bennett, Chief Executive Officer, Consumers Health Forum of Australia, Committee Hansard, 25 July 2011, p. 38.

[47]      Consumers Health Forum of Australia, Submission 9, pp 5–6. See also Cystic Fibrosis Australia, Submission 18, p. 2.

[48]      Private Mental Health Consumer Carer Network (Australia), Submission 1, pp 1–2; Council of Social Service Network, Submission 7, pp 4–5; Novo Nordisk, Submission 23, [p. 2]; Joint submission from Cancer Council Australia, the Clinical Oncological Society of Australia and the Medical Oncology Group of Australia, Submission 32, p. 2.

[49]      Australian Pain Management Association, Submission 14, pp 5–6.

[50]      Council of Social Service Network, Submission 7, pp 4–5.

[51]      Cancer Voices Australia, Submission 8, p. 4.

[52]      Dr Simon Fisher, Medical Director, AstraZeneca Australia, Committee Hansard, 21 July 2011, p. 21.

[53]      Mr Brian Stafford, Submission 3, p. 1.

[54]      Diabetes Australia, Submission 5, [p. 1]; Mr Bruce Goodwin, Managing Director, Janssen-Cilag Australia, Committee Hansard, 21 July 2011, p. 25.

[55]      Mr Bruce Goodwin, Managing Director, Janssen-Cilag Australia, Committee Hansard, 21 July 2011, p. 25.

[56]      National Association of People Living with HIV/AIDS, Submission 6, p. 4.

[57]      Ms Helen Tyrrell, Chief Executive Officer, Hepatitis Australia, Committee Hansard, 25 July 2011, p. 56.

[58]      Consumers Health Forum of Australia, Submission 9, Attachment A 'Keep your Cabinet out of our medicines: Results of a consumer survey on changes to the PBS listing process', April 2011, p. 5. See also Joint submission from Cancer Council Australia, the Clinical Oncological Society of Australia and the Medical Oncology Group of Australia, Submission 32, p. 2; Roche Products, Submission 39, pp 3–4.

[59]      Chronic Illness Alliance, Submission 4, p. 3; Diabetes Australia, Submission 5, [p. 1].

[60]      iNova Pharmaceuticals (Australia), Submission 11, p. 2.

[61]      National Association of People Living with HIV/AIDS, Submission 6, p. 1.

[62]      Ms Elizabeth Trapani, and Ms Chey-Anne Ellsum, Committee Hansard, 21 July 2011, p. 35.

[63]      Mr Robert Pask, National Advocates Program, Multiple Sclerosis Australia, Committee Hansard, 21 July 2011, p. 41.

[64]      Mr Bruce Goodwin, Managing Director, Janssen-Cilag Australia, Committee Hansard, 21 July 2011, pp 25 and 28.

[65]      Mr Rob Baveystock, Managing Director, Mundipharma, Committee Hansard, 21 July 2011, pp 26 and 28.

[66]      Mr Mark Glover, Vice President and Managing Director, Allergan Australia, Committee Hansard, 21 July 2011, p. 20.

[67]      Dr Simon Fisher, Medical Director, AstraZeneca Australia, Committee Hansard, 21 July 2011, p. 20.

[68]      Dr Bill Ketelbey, Country Medical Director, Pfizer Australia, Committee Hansard, 21 July 2011, p. 28

[69]      Dr Bill Ketelbey, Country Medical Director, Pfizer Australia, Committee Hansard, 21 July 2011, p. 28.

[70]      SANE Australia, Submission 10, [p. 1].

[71]      Ms Carol Bennett, Chief Executive Officer, Consumers Health Forum of Australia, Committee Hansard, 25 July 2011, p. 41.

[72]      Mr David Learmonth, Deputy Secretary, Department of Health and Ageing, Committee Hansard, 25 July 2011, p. 2.

[73]      Ms Liliana Bulfone, Senior Research Fellow, Deakin University, Committee Hansard, 21 July 2011, p. 4.

[74]      Consumers Health Forum of Australia, Submission 9, Attachment A 'Keep your Cabinet out of our medicines: Results of a consumer survey on changes to the PBS listing process', April 2011, p. 11.

[75]      SANE Australia, Submission 10, [p. 1]. See also Ms Barbara Hocking, Executive Director, SANE Australia, Committee Hansard, 25 July 2011, pp 49–50; Research Australia, Submission 12, [p. 4].

[76]      Mundipharma, Submission 38, p. 5.

[77]      Consumers Health Forum of Australia, Submission 9, Attachment A 'Keep your Cabinet out of our medicines: Results of a consumer survey on changes to the PBS listing process', April 2011, p. 11. See also Mr Rob Baveystock, Managing Director, Mundipharma, Committee Hansard, 21 July 2011, p. 26.

[78]      Mr Rob Baveystock, Managing Director, Mundipharma, Committee Hansard, 21 July 2011, p. 26.

[79]      Professor Michael Cousins, Director, Painaustralia, Committee Hansard, 21 July 2011, p. 44.

[80]      Emeritus Professor Lloyd Sansom, Chair, Pharmaceutical Benefits Advisory Committee, Committee Hansard, 25 July 2011, p. 23.

[81]      Professor Michael Cousins, Director, Painaustralia, Committee Hansard, 21 July 2011, p. 47.

[82]      Mr David Learmonth, Deputy Secretary, Department of Health and Ageing, Committee Hansard, 25 July 2011, p. 2.

[83]      Mundipharma, Submission 38, p. 15.

[84]      Mr Rob Baveystock, Managing Director, Mundipharma, Committee Hansard, 21 July 2011, p. 26.

[85]      Mr Mark Glover, Vice President and Managing Director, Allergan Australia, Committee Hansard, 21 July 2011, p. 16.

[86]      Mr Mark Glover, Vice President and Managing Director, Allergan Australia, Committee Hansard, 21 July 2011, p. 16.

[87]      Ms Elizabeth Trapani, Committee Hansard, 21 July 2011, pp 34 and 36–37.

[88]      Ms Elizabeth Trapani, Committee Hansard, 21 July 2011, pp 34 and 36–37.

[89]      Mr Mark Glover, Vice President and Managing Director, Allergan Australia, Committee Hansard, 21 July 2011, p. 17.

[90]      Ms Chey-Anne Ellsum, Committee Hansard, 21 July 2011, pp 34–35.

Chapter 6 - Consequences for the pharmaceutical sector and the availability of medicines in Australia

[1]        Amgen Australia, Submission 42, [p. 1].

[2]        Ms Kate Lynch, Chief Executive Officer, and Mr Robert Ellis, Board Member, Generic Medicines Industry Association, Committee Hansard, 21 July 2011, p. 15.

[3]        National Association of People Living with HIV/AIDS, Submission 6, pp 3–4; Consumers Health Forum of Australia, Submission 9, p. 4; Ms Liliana Bulfone, Senior Research Fellow, Deakin University, Committee Hansard, 21 July 2011, pp 1–3.

[4]        National Association of People Living with HIV/AIDS, Submission 6, p. 4.

[5]        Ms Liliana Bulfone, Senior Research Fellow, Deakin University, Committee Hansard, 21 July 2011, p. 3; Roche Products, Submission 39, p. 4.

[6]        Medicines Australia, Submission 36, pp 8 and 16.

[7]        Mr Andrew Bruce, Executive Director, Health Policy and Research, Medicines Australia, Committee Hansard, 25 July 2011, p. 28.

[8]        Dr Brendan Shaw, Chief Executive, Medicines Australia, Committee Hansard, 25 July 2011, p. 31.

[9]        Allergan Australia, Submission 45, p. 7.

[10]      Janssen-Cilag, Submission 37, p. 9.

[11]      Ms Liliana Bulfone, Senior Research Fellow, Deakin University, Committee Hansard, 21 July 2011, p. 1.

[12]      Mr David Learmonth, Deputy Secretary, Department of Health and Ageing, Committee Hansard, 25 July 2011, pp 7–8.

[13]      Mr John Latham, Chairman and Managing Director, Pfizer Australia, Committee Hansard, 21 July 2011, p. 29. See also Sanofi, Submission 29, [p. 2]; Mr Jose Vieira, Managing Director, AstraZeneca Australia, Committee Hansard, 21 July 2011, pp 19‑20.

[14]      iNova Pharmaceuticals (Australia), Submission 11, p. 2. See also Joint submission from Cancer Council Australia, the Clinical Oncological Society of Australia and the Medical Oncology Group of Australia, Submission 32, p. 2; Amgen Australia, Submission 42, [pp 1–2].

[15]      Mr John Latham, Chairman and Managing Director, Pfizer Australia, Committee Hansard, 21 July 2011, p. 27. See also Pfizer Australia, Submission 35, p. 17.

[16]      Mr Bruce Goodwin, Managing Director, Janssen-Cilag Australia, Committee Hansard, 21 July 2011, p. 32.

[17]      Ms Kate Lynch, Chief Executive Officer, Generic Medicines Industry Association, Committee Hansard, 21 July 2011, p. 15.

[18]      Medicines Australia, Submission 36, p. 15.

[19]      Mr David Learmonth, Deputy Secretary, Department of Health and Ageing, Committee Hansard, 25 July 2011, p. 16.

[20]      Pfizer Australia, answers to questions on notice and additional information, [pp 1–2].

[21]      Mundipharma, answers to questions on notice and additional information, 21 July 2011, p. 7.

[22]      Mr Jose Vieira, Managing Director, AstraZeneca Australia, Committee Hansard, 21 July 2011, p. 20. See also Mr Mark Glover, Vice President and Managing Director, Allergan Australia, Committee Hansard, 21 July 2011, p. 20.

[23]      Dr John Whitlam, Medical Affairs Director, Mundipharma, Committee Hansard, 21 July 2011, p. 31.

[24]      Mundipharma, answers to questions on notice and additional information, 21 July 2011, p. 7.

[25]      Mr Jose Vieira, Managing Director, AstraZeneca Australia, Committee Hansard, 21 July 2011, p. 20.

[26]      GlaxoSmithKline Australia, Submission 44, p. 2.

[27]      Mr Jose Vieira, Managing Director, AstraZeneca Australia, Committee Hansard, 21 July 2011, pp 23–24. See also Mr Bruce Goodwin, Managing Director, Janssen-Cilag Australia, Committee Hansard, 21 July 2011, p. 32; Roche Products, Submission 39, p. 5.

[28]      Mr Rob Baveystock, Managing Director, Mundipharma, Committee Hansard, 21 July 2011, pp 31–32.

[29]      AstraZeneca Australia, Submission 47, pp 6–7.

[30]      Mr David Learmonth, Deputy Secretary, Department of Health and Ageing, Committee Hansard, 25 July 2011, p. 2.

[31]      Mr John Latham, Chairman and Managing Director, Pfizer Australia, Committee Hansard, 21 July 2011, p. 28. See also Dr Brendan Shaw, Chief Executive, and Mr Andrew Bruce, Executive Director, Health Policy and Research, Medicines Australia, Committee Hansard, 25 July 2011, p. 31.

[32]      Consumers Health Forum of Australia, Submission 9, Attachment A, 'Keep your Cabinet out of our medicines: Results of a consumer survey on changes to the PBS listing process', p. 9.

[33]      Pfizer Australia, Submission 35, p. 5.

[34]      Medicines Australia, Submission 36, p. 9.

[35]      Dr Brendan Shaw, Chief Executive, Medicines Australia, Committee Hansard, 25 July 2011, p. 30.

[36]      Dr Simon Fisher, Medical Director, AstraZeneca Australia, Committee Hansard, 21 July 2011, p. 24.

[37]      GlaxoSmithKline Australia, Submission 44, p. 11.

[38]      Janssen-Cilag, Submission 37, p. 13.

[39]      Pfizer Australia, answers to questions on notice and additional information, [p. 2].

[40]      Research Australia, Submission 12, [p. 3]. See also Novo Nordisk, Submission 23, [p. 2].

[41]      Mr David Menadue, Special Representative, National Association of People Living with HIV/AIDS, Committee Hansard, 21 July 2011, pp 48–49.

[42]      Mr John Stubbs, Executive Officer, Cancer Voices Australia, Committee Hansard, 25 July 2011, p. 45.

[43]      Mr David Learmonth, Deputy Secretary, Department of Health and Ageing, Committee Hansard, 25 July 2011, p. 9.

[44]      National Association of People Living with HIV/AIDS, Submission 6, pp 2–3.

[45]      National Association of People Living with HIV/AIDS, Submission 6, p. 3; Consumers Health Forum of Australia, Submission 9, p. 4; Sanofi, Submission 29, [p. 1].

[46]      Consumers Health Forum of Australia, Submission 9, p. 4.

[47]      AstraZeneca Australia, Submission 47, p. 8. See also Allergan Australia, Submission 45, p. 8.

[48]      National Association of People Living with HIV/AIDS, Submission 6, p. 2. See also Research Australia, Submission 12, [p. 3].

[49]      Dr Brendan Shaw, Chief Executive, Medicines Australia, Committee Hansard, 25 July 2011, p. 27. See also Novo Nordisk, Submission 23, [p. 2].

[50]      Deakin Health Economics, Deakin University, Submission 19, p. 6.

[51]      Mr Mark Glover, Vice President and Managing Director, Allergan Australia, Committee Hansard, 21 July 2011, p. 19.

[52]      Mr Jose Vieira, Managing Director, AstraZeneca Australia, Committee Hansard, 21 July 2011, pp 19‑20.

[53]      Mr Andrew Bruce, Executive Director, Health Policy and Research, Medicines Australia, Committee Hansard, 25 July 2011, p. 27.

[54]      iNova Pharmaceuticals (Australia), Submission 11, p. 2.

[55]      Janssen-Cilag, Submission 37, p. 12.

[56]      Ms Liliana Bulfone, Senior Research Fellow, Deakin University, Committee Hansard, 21 July 2011, p. 4.

[57]      Dr Brendan Shaw, Chief Executive, Medicines Australia, Committee Hansard, 25 July 2011, p. 30.

Chapter 7 - Conclusions and recommendations

[1]        Commonwealth Government, Portfolio Budget Statements 2011–12: Budget Related Paper No. 1.10: Health and Ageing Portfolio, Commonwealth of Australia, Canberra, 2011, p. 121.

Government senator's minority report

[1]        Department of Health and Ageing, Submission 46, p. 21.

[2]        Mr David Learmonth, Deputy Secretary, Department of Health and Ageing, Committee Hansard, 25 July 2011, p. 2.

[3]        Mr Robert Pask, National Advocates Program, Multiple Sclerosis Australia, Committee Hansard, 21 July 2011, p. 41.

[4]        Mr John Latham, Chairman and Managing Director, Pfizer Australia, Committee Hansard, 21 July 2011, p. 27.

[5]        The Hon. Nicola Roxon, MP, Minister for Health and Ageing, 'Opening Address to Consumers Health Forum PBS Summit', Speech, 29 April 2011, [p. 2].

[6]        Mr David Learmonth, Deputy Secretary, Department of Health and Ageing, Committee Hansard, 25 July 2011, p. 7.

[7]        Ms Carol Bennett, Chief Executive Officer, Consumers Health Forum of Australia, Committee Hansard, 25 July 2011, p. 36.

[8]        Mr Mark Glover, Vice President and Managing Director, Allergan Australia, Committee Hansard, 21 July 2011, p. 22.

[9]        Emeritus Professor Lloyd Sansom, AO, Chair, Pharmaceutical Benefits Advisory Committee, Committee Hansard, 25 July 2011, p. 23.

[10]      The Hon. Nicola Roxon, MP, Minister for Health and Ageing, Transcript of Doorstop, 25 February 2011, [p. 1].

[11]      The Hon. Nicola Roxon, MP, Minister for Health and Ageing, 'Patients Benefit from New Medicines Listed on the PBS and NIP', Media Release, 25 February 2011, [p. 2].

[12]      Mr David Learmonth, Deputy Secretary, Department of Health and Ageing, Committee Hansard, 25 July 2011, p. 1.

[13]      The Hon. Nicola Roxon, MP, Minister for Health and Ageing, 'Patients Benefit from New Medicines Listed on the PBS and NIP', Media Release, 25 February 2011, [p. 2].

[14]      Mr David Learmonth, Deputy Secretary, Department of Health and Ageing, Committee Hansard, 25 July 2011, p. 1.

[15]      Emeritus Professor Lloyd Sansom, AO, Chair, Pharmaceutical Benefits Advisory Committee, answers to questions on notice, 25 July 2011, [p. 1].

[16]      Mr David Learmonth, Deputy Secretary, Department of Health and Ageing, Committee Hansard, 25 July 2011, p. 12.

[17]      Emeritus Professor Lloyd Sansom, AO, Chair, Pharmaceutical Benefits Advisory Committee, answers to questions on notice, 25 July 2011, [p. 1].

[18]      Mr David Learmonth, Deputy Secretary, Department of Health and Ageing, Committee Hansard, 25 July 2011, p. 11.

[19]      Department of Health and Ageing, Submission 46, p. 15.

[20]      Department of Health and Ageing, Submission 46, p. 15.

[21]      The Hon. Nicola Roxon, MP, Minister for Health and Ageing, Transcript of Doorstop, 21 June 2011, [p. 1].

[22]      The Hon. Nicola Roxon, MP, Minister for Health and Ageing, House of Representatives Hansard, 25 May 2011, p. 4753.

[23]      Ms Liliana Bulfone, Senior Research Fellow, Deakin University, Committee Hansard, 21 July 2011, p. 2.

[24]      The Hon. Nicola Roxon, MP, Minister for Health and Ageing, Transcript of Doorstop, 25 February 2011, [p. 4].

[25]      The Hon. Nicola Roxon, MP, Minister for Health and Ageing, 'Opening Address to Consumers Health Forum PBS Summit', Speech, 29 April 2011, [p. 3].

[26]      Department of Health and Ageing, Submission 46, p. 7.

[27]      Mr David Carvalho, First Assistant Secretary, Social Policy Division, Budget Group, Department of Finance and Deregulation, Committee Hansard, 25 July 2011, p. 11.

[28]      Mr David Learmonth, Deputy Secretary, Department of Health and Ageing, Committee Hansard, 25 July 2011, p. 11.

[29]      Ms Kate Lynch, Chief Executive Officer, Generic Medicines Industry Association, Committee Hansard, 21 July 2011, p. 7.

[30]      Ms Liliana Bulfone, Senior Research Fellow, Deakin University, Committee Hansard, 21 July 2011, p. 4.

[31]      Department of Health and Ageing, Submission 46, p. 18, citing The Hon. Nicola Roxon, MP, Minister for Health and Ageing, second reading speech, National Health Amendment (Pharmaceutical Benefits Scheme) Bill 2010, House of Representatives Hansard, 29 September 2010, p. 80.

[32]      Dr Brendan Shaw, Chief Executive, Medicines Australia, Committee Hansard, 25 July 2011, p. 25.

[33]      Mr David Learmonth, Deputy Secretary, Department of Health and Ageing, Committee Hansard, 25 July 2011, p. 2.

[34]      Department of Health and Ageing, Submission 46, p. 19.

[35]      Mr David Learmonth, Deputy Secretary, Department of Health and Ageing, Committee Hansard, 25 July 2011, p. 1.

[36]      Mr David Learmonth, Deputy Secretary, Department of Health and Ageing, Committee Hansard, 25 July 2011, p. 2.

[37]      Mr John Latham, Chairman and Managing Director, Pfizer Australia, Committee Hansard, 21 July 2011, p. 28.

[38]      Mr David Learmonth, Deputy Secretary, Department of Health and Ageing, Committee Hansard, 25 July 2011, p. 2.

[39]      Mr Jose Vieira, Managing Director, AstraZeneca Australia, Committee Hansard, 21 July 2011, pp 3–4; Mr Bruce Goodwin, Managing Director, Janssen-Cilag Australia Pty Ltd, Committee Hansard, 21 July 2011, p. 32.

[40]      Mr David Learmonth, Deputy Secretary, Department of Health and Ageing, Committee Hansard, 25 July 2011, p. 2.

[41]      Mr David Learmonth, Deputy Secretary, Department of Health and Ageing, Committee Hansard, 25 July 2011, p. 5.

[42]      Mr David Learmonth, Deputy Secretary, Department of Health and Ageing, Committee Hansard, 25 July 2011, pp 9–10.

[43]      Mr David Learmonth, Deputy Secretary, Department of Health and Ageing, Committee Hansard, 25 July 2011, pp 6–7.

[44]      Mr Mark Glover, Vice President and Managing Director, Allergan Australia, Committee Hansard, 21 July 2011, p. 20. See also Mr Jose Vieira, Managing Director, AstraZeneca Australia, Committee Hansard, 21 July 2011, p. 20.

[45]      Department of Health and Ageing, Submission 46, p. 11.

[46]      Emeritus Professor Lloyd Sansom, Chair, Pharmaceutical Benefits Advisory Committee, Committee Hansard, 25 July 2011, p. 22.

[47]      Mr David Learmonth, Deputy Secretary, Department of Health and Ageing, Committee Hansard, 25 July 2011, p. 9.

[48]      Medicines Australia, answers to questions on notice 25 July 2011, [p. 4]

[49]      Medicines Australia, answers to questions on notice 25 July 2011, [p. 5].

[50]      Mr David Learmonth, Deputy Secretary, Department of Health and Ageing, Committee Hansard, 25 July 2011, p. 9.

[51]      Ms Liliana Bulfone, Senior Research Fellow, Deakin University, Committee Hansard, 21 July 2011, p. 4.

[52]      Mr Rob Baveystock, Managing Director, Mundipharma Pty Ltd, Committee Hansard, 21 July 2011, p. 31.

[53]      Dr Simon Fisher, Medical Director, AstraZeneca Australia Pty Ltd, Committee Hansard, 21 July 2011, p. 21.

[54]      Department of Health and Ageing, Submission 46, p. 10.

[55]      Mr David Learmonth, Deputy Secretary, Department of Health and Ageing, Committee Hansard, 25 July 2011, p. 2.

[56]      Emeritus Professor Lloyd Sansom, Chair, Pharmaceutical Benefits Advisory Committee, Committee Hansard, 25 July 2011, p. 22. See also Ms Liliana Bulfone, Senior Research Fellow, Deakin University, Committee Hansard, 21 July 2011, p. 4.

[57]      Mr David Learmonth, Deputy Secretary, Department of Health and Ageing, Committee Hansard, 25 July 2011, p. 6.

[58]      Mr Mark Glover, Vice President and Managing Director, Allergan Australia, Committee Hansard, 21 July 2011, p. 19.

[59]      Mr John Latham, Chairman and Managing Director, Pfizer Australia, Committee Hansard, 21 July 2011, p. 28.

Australian Greens Additional Comments

[1]        The Hon. Nicola Roxon, MP, Minister for Health and Ageing, Commonwealth of Australia, Transcript, Press Conference-Canberra, 21 June 2011, [p.4].

[2]        Dr Brendan Shaw, Chief Executive, Medicines Australia, Committee Hansard, 25 July 2011, p. 25; Australian Medical Association, Submission 16, pp 3–4; Generic Medicines Industry Association, Submission 31, pp 4 and 6–7; Mr John Latham, Chairman and Managing Director, Pfizer Australia, Committee Hansard, 21 July 2011, p. 31; Chronic Illness Alliance, Submission 4, pp 5–6.

[3]        Chronic Illness Alliance, Submission 4, pp 5–6; Generic Medicines Industry Association, Submission 31, pp 5–7; Mr John Latham, Chairman and Managing Director, Pfizer Australia, Committee Hansard, 21 July 2011, p. 31.

[4]        Bulfone, Liliana. High prices for generics in Australia: More competition might help [ZPaper in special issue: The Pharmaceutical Benefits Scheme and the Dilemmas of Medicines Policy. Lofgren, Hans (ed).] [online]. Australian Health Review, v.33, no. 2, May 2009: 200–214. <http://search.informit.com.au/fullText;dn=200909889;res=APAFT>

[5]        Clarke PM, Fitzgerald EM. Expiry of patent protection on statins: effects on Pharmaceutical expenditure in Australia. Med J Aust 2010; 192: 633-636.

[6]        Ms Kate Lynch, Chief Executive Officer, and Mr Robert Ellis, Board Member, Generic Medicines Industry Association, Committee Hansard, 21 July 2011, pp 10–11; Generic Medicines Industry Association, Submission 31, p. 5.

[7]        The Generic Medicines Industry Association suggests, for instance, that the delay (by Sanofi-Aventis) in the introduction of generic clopidogrel in Australia cost the PBS over $60 million.